PCN300 EVALUATION OF OVERALL SURVIVAL ASSOCIATED WITH CHANGE IN DOSING OF BORTEZOMIB, MELPHALAN, AND PREDNISONE REGIMEN IN TRANSPLANT INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: A REAL-WORLD STUDY
Abstract
Authors
M. Mehra R. Potluri A. Lam M. Slavcev